There are currently no standard treatments that slow or stop Parkinson’s disease — available therapies address each patient’s individual symptoms. Now, a breakthrough study successfully identifies two existing antimalaria drugs that show promise in targeting disease progress.
The international team behind the study — including members from Nanyang Technological University (NTU) in Singapore and McLean Hospital and Harvard Medical School in Belmont, MA — reports the findings in the Proceedings of the National Academy of Sciences.
An estimated 10 million people worldwide are living with Parkinson’s disease — a progressive, neurological disorder that mostly strikes after middle age.
This article originally appeared on Psychiatry Advisor
READ FULL ARTICLE From Medical News Today